Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

121. Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update

Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update CANADIAN ASSOCIATION OF GASTROENTEROLOGY L’ASSOCIATION CANADIENNE DE GASTROENTEROLOGIE CAG/ACG National Office, 224 – 1540 Cornwall Road, Oakville, ON, Canada L6J 7W5 Telephone: 905.829.2504 Toll free: 1.888.780.0007 Fax: 905.829.0242 E-mail: CAGOffice@cag-acg.org Website: http://www.cag-acg.org CAG Position Statement: Hip fracture and proton pump inhibitor therapy (...) – a 2013 update Paul Moayyedi, Bsc, MB ChB, PhD, MPH, FRCP, FRCPC, AGAF, FACG Yuhong Yuan, MSc, MD, PhD Grigorios Leontiadis, MD, PhD on behalf of the CAG Clinical Affairs Health Canada have recently provided an information update on proton pump inhibitor (PPI) therapy and risk of fracture in April 2013 (1) stating “Several scientific studies suggest that PPI therapy may be associated with a small increased risk for fractures of the hip, wrist, or spine related to osteoporosis, a disease resulting

2013 CPG Infobase

122. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Full Text available with Trip Pro

Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Treatment with proton pump inhibitors (PPIs) improves clinical outcomes in patients with peptic ulcer bleeding. However, the optimal dose and route of administration of PPIs remains controversial.To evaluate the efficacy of different regimens of PPIs in the management of acute peptic ulcer bleeding using evidence from direct comparison randomized controlled trials (RCTs).We specifically intended

2013 Cochrane

123. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis

Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

124. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

125. Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis (Abstract)

Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis Critically ill patients may develop bleeding caused by stress ulceration. Acid suppression is commonly prescribed for patients at risk of stress ulcer bleeding. Whether proton pump inhibitors are more effective than histamine 2 receptor antagonists is unclear.To determine the efficacy and safety of proton pump inhibitors vs. histamine 2 (...) receptor antagonists for the prevention of upper gastrointestinal bleeding in the ICU.We searched Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, ACPJC, CINHAL, online trials registries (clinicaltrials.gov, ISRCTN Register, WHO ICTRP), conference proceedings databases, and reference lists of relevant articles.Randomized controlled parallel group trials comparing proton pump inhibitors to histamine 2 receptor antagonists for the prevention of upper gastrointestinal bleeding

2013 EvidenceUpdates

126. The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review

The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review "The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngophar" by Wendy Kellam < > > > > > Title Author Date of Graduation Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into the throat. The current standard of care is to treat (...) patients with a proton pump inhibitor (PPI) twice daily for up to 6 months or longer. Two meta-analyses were completed in 2006 and found no evidence PPI therapy is better than placebo for chronic laryngitis. Since that time new tools have been created to measure outcomes in this field of research, the Reflux Finding Score (RFS) and Reflux Symptom Index (RSI). Using these standardized measures are researchers able to demonstrate PPI therapy is efficacious in the treatment of LPR? Method: An exhaustive

2013 Pacific University EBM Capstone Project

127. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine

128. Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding?

Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding? Systematic Review Snapshot TAKE-HOME MESSAGE In patients with acute upper gastrointestinal bleeding, proton-pump inhibitor treatment before indexendoscopydoesnotimprovepatient-importantoutcomes. Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding? EBEM Commentators Jennifer C. Cabot, MD Kaushal Shah, MD Department of Emergency Medicine (...) Mount Sinai Hospital New York, NY Results Six trials with a total of 2,223 partici- pants were included. All studies were randomized controlled trials with a parallel-group design, conducted in a hospital setting. Four trials were con- ducted in Europe and 2 in Asia. There was no signi?cant heterogeneity among the trials (Table 2). Compared with the control group, proton-pump inhibitor treatment did not affect the rates of 30-day mortality, rebleeding, surgery, or blood transfusion (Table 1

2013 Annals of Emergency Medicine Systematic Review Snapshots

129. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Full Text available with Trip Pro

Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Barkun AN, Adam V, Martel M, Bardou M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of two types of drug to prevent stress ulcer bleeding in patients in the intensive care unit. The authors concluded that a proton pump inhibitor was more efficient than a histamine 2-receptor antagonist in preventing bleeding from a stress ulcer

2013 NHS Economic Evaluation Database.

130. Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection

Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Article Text Aetiology Systematic review

2013 Evidence-Based Medicine

131. Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study

Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Article Text Aetiology Cohort study Proton pump inhibitors do

2013 Evidence-Based Medicine

132. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review Full Text available with Trip Pro

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review Clopidogrel as an adjunct to aspirin has improved outcomes after acute coronary syndromes, but laboratory studies suggest a reduced antiplatelet effect when proton pump inhibitors (PPIs) are co-administered. Despite corroborating data from retrospective studies, new clinical data fuel the controversy on this issue.Systematic review of the impact of the addition

2013 EvidenceUpdates

133. Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices

Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The association between proton pump inhibitor use and hip fracture cannot be explained by differences

2013 Evidence-Based Medicine

134. Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review

Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

135. [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]

[Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public (...) d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante et en services sociaux (INESSS

2012 Health Technology Assessment (HTA) Database.

136. Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. (Abstract)

Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. 22910967 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. JC2-13 10.7326/0003-4819-157-4-201208210-02013 Koretz Ronald L RL Olive View-UCLA Medical Center Sylmar, California, USA. eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

137. Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis (Abstract)

Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis H2-receptor antagonists (H2RA) have been shown to reduce stress-related mucosal bleeding (SRMB), yet randomized controlled trials assessing proton pump inhibitors (PPIs) have yielded conflicting results. The objective of this study was to evaluate the efficacy of PPIs vs. H2RAs in the prophylaxis of SRMB in critically ill adults with risk

2012 EvidenceUpdates

138. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial Full Text available with Trip Pro

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor

2012 EvidenceUpdates Controlled trial quality: predicted high

139. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

140. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Full Text available with Trip Pro

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. To examine the association between chronic use of proton pump inhibitors (PPIs) and risk of hip fracture.Prospective cohort study.Nurses' Health Study, which originally recruited from the 11 most populous states in the US.79,899 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PPIs and other risk factors biennially since 2000

2012 BMJ